These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751 [TBL] [Abstract][Full Text] [Related]
3. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]. Kobayashi H Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830 [TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577 [TBL] [Abstract][Full Text] [Related]
5. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Schmitt M; Jänicke F; Graeff H Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250 [TBL] [Abstract][Full Text] [Related]
6. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler WA; Jänicke F; Graeff H J Biol Chem; 1991 Mar; 266(8):5147-52. PubMed ID: 1900515 [TBL] [Abstract][Full Text] [Related]
7. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Kobayashi H; Moniwa N; Sugimura M; Shinohara H; Ohi H; Terao T Biochim Biophys Acta; 1993 Jul; 1178(1):55-62. PubMed ID: 8329457 [TBL] [Abstract][Full Text] [Related]
8. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148 [TBL] [Abstract][Full Text] [Related]
9. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler WA; Jänicke F; Graeff H FEBS Lett; 1992 Feb; 297(1-2):112-8. PubMed ID: 1551416 [TBL] [Abstract][Full Text] [Related]
10. [The urokinase-type plasminogen activator system and its role in tumor progression]. Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975 [TBL] [Abstract][Full Text] [Related]
11. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Biliran H; Sheng S Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384 [TBL] [Abstract][Full Text] [Related]
12. RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. Muehlenweg B; Schnelzer A; Türkmen B; Lengyel E; Reuning U; Graeff H; Schmitt M; Magdolen V Methods Mol Med; 2001; 39():299-306. PubMed ID: 21340784 [TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator enhances invasion of human T cells (Jurkat) into a fibrin matrix. Kramer MD; Spring H; Todd RF; Vettel U J Leukoc Biol; 1994 Aug; 56(2):110-6. PubMed ID: 7915295 [TBL] [Abstract][Full Text] [Related]
14. Involvement of urokinase-type plasminogen activator system in cancer: an overview. Mekkawy AH; Pourgholami MH; Morris DL Med Res Rev; 2014 Sep; 34(5):918-56. PubMed ID: 24549574 [TBL] [Abstract][Full Text] [Related]
15. Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin. Schmitt M; Kanayama N; Jänicke F; Hafter R; Graeff H Adv Exp Med Biol; 1991; 297():111-28. PubMed ID: 1837419 [TBL] [Abstract][Full Text] [Related]
16. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804 [TBL] [Abstract][Full Text] [Related]
17. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Plesner T; Behrendt N; Ploug M Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652 [TBL] [Abstract][Full Text] [Related]
19. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Tang L; Han X Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006 [TBL] [Abstract][Full Text] [Related]
20. Pro-urokinase-type plasminogen activator is a substrate for hepsin. Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]